Joseph Haas

Joseph Haas

Senior Writer

Washington, DC

Joe has covered a wide range of biopharmaceutical stories since 2007 and contributes to Scrip, In Vivo, Pink Sheet and related Citeline publications. His specialties include business development, commercial strategies and liver and infectious diseases.

Latest from Joseph Haas

PTC Gets $1bn From Novartis For Phase II Huntington’s Candidate

Novartis will also pay up to $1.9bn for milestones and share US profits on the Phase II RNA-splicing candidate. PTC is discussing potential accelerated approval with the US FDA.

2024’s Busiest Dealmakers: Novartis Laps The Field, While Lilly, Sanofi Keep Busy

Nine biopharma companies made 12 or more deals, with Novartis inking 21 deals and leading M&A activity. Roche, meanwhile, spent little up front but maintained a hectic pace with 12 alliances.

Deal Watch: Sarepta Targets RNAi In Broad Collaboration With Arrowhead

Plus deals involving Novartis with Vyriad, Ratio and Schrödinger; Pharmanovia/Lindis, Pulmatrix/Cullgen, Entero/Journey, Roche/Flare and AlloVir/Kalaris.

Asia Deal Watch: Otsuka Lands Second Alliance With Ionis, Focused On ALS Subpopulation

Plus deals involving Zai Lab/Pfizer, Laekna/Lilly, Takeda/Alloy, Lunit/AstraZeneca, VelaVigo/Avenzo, Biosion/Aclaris, HCW/WY Biotech, Celltrion/iQone and Kaken/Numab.

NASH Updates: Boston Pharma, Viking Line Up As Serious Competitors

Boston Pharma may be rising in the FGF21 space, while Viking could be formidable competition for Madrigal in the THRβ agonist class. Akero will soon report potentially groundbreaking data in cirrhotic NASH.

Novo Nordisk’s Semaglutide Tops Madrigal’s Rezdiffra In NASH

The firm revealed that an analysis of its Phase III ESSENCE trial combining fibrosis reduction and NASH resolution showed a higher effect over placebo than in Madrigal’s pivotal trial.